Beta Bionics Narrows Q1 Net Loss to $21.9M as Revenue Jumps 57%

Beta Bionics, Inc., a diabetes technology company, reported a net loss of $21.9 million for the three months ending March 31, 2026, narrowing from a $28.7 million loss in the same period last year. The improvement came despite a 30% jump in operating loss to $24.3 million from $18.6 million year-over-year. Read more earnings reports.

Revenue climbed 57% to $27.6 million from $17.6 million in the first quarter of fiscal 2025. The revenue increase was driven by growth across key product categories, with one segment more than tripling to $10.2 million from $3.3 million. Another major revenue line jumped 63% to $6.8 million from $4.2 million.

Gross profit nearly doubled to $16.4 million from $9.0 million, as cost of goods sold rose at a slower pace than revenue. Cost of goods sold increased 29% to $11.2 million from $8.7 million in the prior-year quarter.

Operating expenses surged 47% to $40.7 million from $27.6 million. Research and development spending increased 36% to $10.4 million from $7.6 million as the company invested in product development.

Cash and cash equivalents stood at $30.2 million as of March 31, 2026, down from $31.6 million at the end of December 2025 and $42.5 million a year earlier. Short-term investments declined to $169.3 million from $187.5 million at year-end. Cash used in operations was $23.8 million compared to $20.0 million in the first quarter of fiscal 2025.

Total assets decreased to $304.4 million from $328.7 million at the end of fiscal 2025. Inventory rose to $23.7 million from $21.7 million, while accounts receivable fell to $15.8 million from $17.1 million.

The company's accumulated deficit widened to $391.8 million from $369.9 million at the end of December 2025. Total liabilities declined to $33.2 million from $41.1 million, driven by a reduction in accrued liabilities to $17.3 million from $22.4 million.

Basic and diluted loss per share improved to $0.49 from $0.93, based on weighted average shares outstanding of 44.4 million compared to 30.7 million in the prior-year period. Total shares outstanding reached 44.6 million as of March 31, 2026.

Financial Summary